Menu
Back to Journals » Drug Design, Development and Therapy » Volume 8
Evaluation of ceftiofur–PHBV microparticles in rats
Authors Vilos C, Constandil L, Rodas P, Cantin M, Zepeda K, Herrera N, Velasquez L
Received 10 January 2014
Accepted for publication 12 March 2014
Published 29 May 2014 Volume 2014:8 Pages 651—666
DOI https://doi.org/10.2147/DDDT.S60444
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 6
Cristian Vilos,1,3 Luis Constandil,2,3 Paula I Rodas,1,3 Mario Cantin,4,5 Katherine Zepeda,1 Natalia Herrera,1 Luis A Velasquez1,3
1Center for Integrative Medicine and Innovative Science (CIMIS), Faculty of Medicine, Universidad Andres Bello, Santiago, 2Laboratory of Neurobiology, Department of Biology, Faculty of Chemistry and Biology, Universidad de Santiago de Chile, Santiago, 3Centro para el Desarrollo de la Nanociencia y Nanotecnología, Universidad de Santiago de Chile, Ecuador, Santiago, 4CIMA, Department of Integral Dentistry, Faculty of Dentistry, Universidad de La Frontera, Temuco, 5Center of Research in Biomedical Sciences, Universidad Autónoma de Chile, Temuco, Chile
Abstract: Despite the high number of antibiotics used for the treatment of infectious disease in animals, the development of slow release formulations presents a significant challenge, particularly in using novel biomaterials with low cost. In this report, we studied the pharmacokinetics, toxicity, and therapeutic activity of ceftiofur–PHBV (ceftiofur–poly(3-hydroxybutyrate-co-3-hydroxyvalerate)) in rats. The pharmacokinetic study demonstrated a sustained release of ceftiofur into the bloodstream, with detectable levels over the minimum inhibitory concentration for at least 17 days after a single intramuscular injection of ceftiofur–PHBV (10 mg/kg weight). In addition, the toxicological evaluation of biochemical, hematological, and coagulation blood parameters at the therapeutic dose demonstrated the safety of ceftiofur–PHBV, with no adverse effects. In addition, ceftiofur–PHBV exhibited a therapeutic effect for a longer time period than the nonencapsulated ceftiofur in rats challenged with Salmonella Typhimurium. The slow release of ceftiofur from the ceftiofur–PHBV, its low toxicity in the blood parameters evaluated, and the efficacy in the rats infected with Salmonella Typhimurium make ceftiofur–PHBV a strong candidate for biotechnological applications in the veterinary industry.
Keywords: microparticles, drug delivery, Salmonella Typhimurium, rat infection model, blood parameters
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.